Martha Aronson to leave CONMED board for CEO role at Merit Medical

LARGO, Fla. - CONMED Corporation (NYSE:CNMD), a medical technology company with a market capitalization of $1.6 billion and annual revenue of $1.32 billion, announced Monday that board member Martha Aronson will resign effective July 7, 2025, to become President and Chief Executive Officer at Merit Medical. According to InvestingPro analysis, CONMED currently appears undervalued, trading at an attractive P/E ratio of 13.6x.

Aronson, who joined CONMED’s board in February 2016 and previously served as Board Chair, has held various leadership positions during her tenure with the medical technology company.

"We are sincerely grateful to Martha for her years of dedicated service to CONMED," said Pat Beyer, President and Chief Executive Officer of CONMED. "Her guidance and expertise have been invaluable to our Board and to me personally as I stepped into the CEO role."

LaVerne Council, Chair of the Board of Directors, acknowledged Aronson’s "strategic insight and unwavering commitment to excellence" that helped shape the company’s direction.

CONMED, which provides devices and equipment for surgical procedures across specialties including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology, made the announcement in a press release statement.

Merit Medical, where Aronson will assume leadership, is described as a global developer and manufacturer of proprietary medical devices.

In other recent news, Conmed Corporation reported its first-quarter 2025 earnings, which revealed an adjusted earnings per share (EPS) of $0.79, missing analysts’ expectations of $1. The company’s revenue reached $321.3 million, falling short of the projected $332.91 million. Despite these misses, Conmed provided optimistic guidance for future quarters, with revenue growth and EPS improvements expected. Meanwhile, Needham downgraded Conmed’s stock from Buy to Hold, citing concerns about the company’s slowing growth trajectory and high debt levels. Needham now projects Conmed’s long-term growth profile at 4-6% organic revenue growth with 10-12% EPS growth, a more modest outlook than previous estimates.

Additionally, Conmed announced a leadership change with LaVerne Council assuming the role of Independent Chair of its Board of Directors, succeeding Martha Goldberg Aronson. Council brings significant expertise in global operations and information technology to the role. The company emphasized its focus on product innovation, particularly in the BioBrace and AirSeal platforms, which contributed to a positive market reception despite the earnings miss. Conmed’s ongoing supply chain improvements and tariff mitigation efforts are also noteworthy, as the company aims to enhance stability and continuity in its operations. These developments highlight Conmed’s strategic initiatives and challenges in the current market environment.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.